Key Takeaways: Clinical Practice Guidelines for Patient Identification
Shared screening priorities across AASLD, AGA, AACE, ADA 2026, and EASL-EASD-EASO practice guidelines for detecting advanced fibrosis and at-risk MASH.
Notice how major medical organizations across North America and Europe all landed on the exact same two-step game plan: check FIB-4 first using routine bloodwork, and if that number isn't clearly low, follow up with either a FibroScan stiffness check (VCTE) or an ELF blood test. If your routine checkups haven't included a FIB-4 calculation yet and you live with diabetes or obesity, you have every major clinical society backing you up when you ask for it.
Why Early Identification Matters
- Early risk stratification for advanced fibrosis in patients with MASLD/MASH is critical for preventing cirrhosis, portal hypertension, and cardiovascular events.1
- AASLD (2023 & 2025 NILDA), AGA, AACE, ADA (2026), and EASL-EASD-EASO (2024) provide aligned guidance on identifying patients at risk for advanced fibrosis (≥F3) and “at-risk MASH” (NAS ≥4 with F2–F3).1-6
Two-Step Noninvasive Testing Consensus
- First-Line Screening: Adult FIB-4 (<1.3 low risk, or <2.0 at age ≥65) is endorsed as initial triage in T2D, prediabetes, metabolic obesity, and persistent transaminasemia (never in children <18 y).1,2
- Second-Line Stratification: ELF™ and LSM by VCTE™ clarify indeterminate FIB-4 scores and guide specialist referral.1,2,6
Biopsy-Free Treatment Selection & Specialty Alignment
- While histology uniquely visualizes hepatocyte ballooning, AASLD now defines biopsy-free NIT thresholds (eg, VCTE 8–15 kPa, MRE 3.1–4.4 kPa, ELF 9.2–10.5) to select non-cirrhotic F2–F3 MASH patients for approved pharmacotherapy, while cardiology (AHA), pediatric (NASPGHAN), and global (APASL/SRU/Baveno VII) societies add population-specific rules.1-7